Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 13/20 | 0.38 |
| ▸ | FLT3 | P36888 | 2/20 | 0.37 |
| ▸ | PTK2 | Q05397 | 3/20 | 0.34 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15617463 | 0.92 | CHEK1 (0.39) | CHEK1PTK2TNK2 | |
| SCHEMBL15036413 | 0.80 | TNK2 (0.34) | CHEK1TNK2 | |
| SCHEMBL15036478 | 0.77 | CDK4 (0.37) | CHEK1FLT3 | |
| SCHEMBL15036381 | 0.76 | PTK2 (0.38) | PTK2TNK2 | |
| SCHEMBL10192632 | 0.76 | CDK4 (0.46) | FLT3PTK2 | |
| SCHEMBL15041550 | 0.74 | PTK2 (0.51) | PTK2TNK2 | |
| SCHEMBL15036432 | 0.74 | TNK2 (0.39) | FLT3TNK2 | |
| SCHEMBL15036273 | 0.73 | CDK4 (0.35) | CHEK1FLT3TNK2 | |
| SCHEMBL15617452 | 0.73 | CDK4 (0.35) | CHEK1FLT3PTK2TNK2 | |
| SCHEMBL15618075 | 0.73 | MAPK14 (0.35) | FLT3TNK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8680099-B2 | 6-(ethynyl)pyrido[2,3-D]pyrimidin-7(8H)-ones for the treatment of CNS disorders | AFRAXIS HOLDINGS, INC. (US) | 2014-03-25 | — | — | US | disclosed |
| US-20130245012-A1 | 6-(ETHYNYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS | AFRAXIS, INC. (US) | 2013-09-19 | — | — | US | disclosed |
| US-20130245012-A1 | 6-(ETHYNYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS | AFRAXIS, INC. (US) | 2013-09-19 | — | — | US | disclosed |
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | AFRAXIS, INC. (US) | 2013-06-20 | — | — | US | disclosed |
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | AFRAXIS, INC. (US) | 2013-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130245012-A1 | 6-(ETHYNYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS | PAK2, PAK6, PAK3 | CHEK1 460/4885FLT3 661/4885PTK2 80/4885 |
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | PAK5, PAK2, PAK6 | CHEK1 212/4885FLT3 811/4885PTK2 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.